Dicerna Pharma (DRNA) PT Raised To $26 At SunTrust On Pivotal Phase I Launch

March 12, 2019 9:04 AM

SunTrust analyst, Edward Nash, reiterated his Buy rating on shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found